10:29 AM
 | 
Feb 27, 2019
 |  BC Extra  |  Clinical News

Novartis first partner in RWE collaboration for dermatology

PharmaSolutions Inc. announced on Wednesday that Novartis AG (NYSE:NOV; SIX:NOVN) will be the first biopharma collaborator in its TARGET-DERM real-world evidence generation program.

TARGET-DERM will gather real world, de-identified patient-level data from electronic medical records as well as claims data, starting with atopic dermatitis and eventually adding other immune-mediated inflammatory skin conditions.

Additionally, TARGET-DERM is collecting patient-reported outcome (PRO) data from surveys and has a biorepository. The program doesn't collect data from wearable devices, but PharmaSolutions Chair Meg Powell said the company is evaluating these technologies and may include them in...

Read the full 433 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >